Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR)

BACKGROUND: The overactivation of mineralocorticoid receptor (MR) plays a key pathological role in the progression of cardiovascular and renal diseases by promoting pro-inflammatory and pro-fibrotic signaling. Recently, it has been found that finerenone, a novel nonsteroidal selective MR antagonist,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Atsushi, Shibata, Hirotaka, Imai, Takumi, Yoshida, Hisako, Miyazono, Motoaki, Takahashi, Naohiko, Fukuda, Daiju, Okada, Yosuke, Teragawa, Hiroki, Suwa, Satoru, Kida, Keisuke, Moroi, Masao, Taguchi, Isao, Toyoda, Shigeru, Shimabukuro, Michio, Tanabe, Kengo, Tanaka, Kenichi, Nangaku, Masaomi, Node, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391880/
https://www.ncbi.nlm.nih.gov/pubmed/37525257
http://dx.doi.org/10.1186/s12933-023-01928-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391880/
https://www.ncbi.nlm.nih.gov/pubmed/37525257
http://dx.doi.org/10.1186/s12933-023-01928-y

Ejemplares similares